1. Home
  2. BTAI vs QRHC Comparison

BTAI vs QRHC Comparison

Compare BTAI & QRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

N/A

Current Price

$0.75

Market Cap

24.8M

Sector

Health Care

ML Signal

N/A

Logo Quest Resource Holding Corporation

QRHC

Quest Resource Holding Corporation

N/A

Current Price

$1.47

Market Cap

25.9M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
BTAI
QRHC
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Environmental Services
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
25.9M
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
BTAI
QRHC
Price
$0.75
$1.47
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
773.5K
29.6K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
75.63
N/A
EPS
N/A
N/A
Revenue
N/A
$138,346,327.00
Revenue This Year
$197.82
$3.67
Revenue Next Year
$910.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.81
52 Week High
$5.19
$2.41

Technical Indicators

Market Signals
Indicator
BTAI
QRHC
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BTAI
QRHC

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About QRHC Quest Resource Holding Corporation

Quest Resource Holding Corp is a national provider of waste and recycling services to customers from across multiple industry sectors that are typically larger, multi-location businesses. The company creates customer-specific programs and perform the related services for the collection, processing, recycling, disposal, and tracking of waste streams and recyclables. The company's services focus on the waste streams and recyclables from box, grocers, and other specialty retailers; automotive after-market operations such as automotive maintenance, quick lube, dealerships, and collision repair; transportation, logistics, and fleet operators; manufacturing and industrial facilities; multi-family and commercial properties; restaurant chains and food operations, etc.

Share on Social Networks: